Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023 16:30 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas
November 09, 2023 07:30 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control
November 03, 2023 12:00 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 12, 2023 11:00 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894
October 11, 2023 07:30 ET
|
Phio Pharmaceuticals Corp.
--Preclinical data shows melanoma cells treated with PH-894 makes them more recognizable to immune cells, increasing potential for elimination --Preclinical data demonstrates the effectiveness of...
RNAi Drug Delivery Technologies and Global Market Analysis Report 2023: Historic Market Revenue from 2020 to 2022, Estimates for 2023, and CAGR Projections through to 2028
August 29, 2023 07:08 ET
|
Research and Markets
Dublin, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The "RNAi Drug Delivery: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global RNAi drug delivery...
RNA Therapy Clinical Trials Market Report 2023-2030: Strategies and Collaborations Shaping the Industry
August 29, 2023 04:48 ET
|
Research and Markets
Dublin, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The "RNA Therapy Clinical Trials Market Size, Share & Trends Analysis Report, 2023-2030" report has been added to ResearchAndMarkets.com's offering. ...
Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute
August 21, 2023 07:30 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 16:30 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
RNA Therapeutics Markets, 2035 - Technical and Financial Perspective on How the Opportunity in this Domain is Likely to Evolve
April 24, 2023 03:33 ET
|
Research and Markets
Dublin, April 24, 2023 (GLOBE NEWSWIRE) -- The "Investor Series: Opportunities in RNA Therapeutics Market" report has been added to ResearchAndMarkets.com's offering. The Investor Series:...